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Abstract
Background: Mesenchymal stem cells (MSCs) are a pluripotent cell type that can differentiate into adipocytes, osteoblasts
and other cells. The reciprocal relationship between adipogenesis and osteogenesis was previously demonstrated; however,
the mechanisms remain largely unknown.
Methods and Findings: We report that activation of PKA by 3-isobutyl-1 methyl xanthine (IBMX) and forskolin enhances
adipogenesis, the gene expression of PPARc2 and LPL, and downregulates the gene expression of Runx2 and osteopontin,
markers of osteogenesis. PKA activation also decreases the ratio of Receptor Activator of the NF-kB Ligand to
Osteoprotegerin (RANKL/OPG) gene expression – the key factors of osteoclastogenesis. All these effects are mediated by the
cAMP/PKA/CREB pathway by suppressing leptin, and may contribute to PKA stimulators-induced in vivo bone loss in
developing zebrafish.
Conclusions: Using MSCs, the center of a newly proposed bone metabolic unit, we identified cAMP/PKA signaling, one of
the many signaling pathways that regulate bone homeostasis via controlling cyto-differentiation of MSCs and altering
RANKL/OPG gene expression.
Citation: Yang D-C, Tsay H-J, Lin S-Y, Chiou S-H, Li M-J, et al (2008) cAMP/PKA Regulates Osteogenesis, Adipogenesis and Ratio of RANKL/OPG mRNA Expression
in Mesenchymal Stem Cells by Suppressing Leptin. PLoS ONE 3(2): e1540. doi:10.1371/journal.pone.0001540
Editor: Neil Hotchin, University of Birmingham, United Kingdom
Received July 26, 2007; Accepted January 11, 2008; Published February 6, 2008
Copyright:  2008 Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: National Scientific Council (NSC-95-2314-B-075-047-MY3, NSC-95-2627-B-010-009-, NSC-96-2627-B-010-009-) and grants from National Yang-Ming
University, Ministry of Education, Aim for the Top University Plan, and Veterans General Hospital-Taipei (V95E1-002 & V95E1-003).
Competing Interests: The authors have declared that no competing interests exist.
*E-mail: hungsc@vghtpe.gov.tw
Introduction
Bone remodeling has long been considered to be controlled
through the bone multicellular or metabolic unit (BMU), which
contains two cellular activities: osteoclastic bone resorption and
osteoblastic bone formation. However, recent genetic studies have
shown that there is no obligatory tight cross-control of bone
formation and bone resorption in vivo. In osteopetrotic patients, the
osteoclasts are either absent or non-functional, yet bone formation
is unaltered [1]. The osteopenic transgenic mice, in which
osteoblast ablation leads to a complete arrest of bone formation
accompanied by bone loss, illustrate that the bone-resorption
function is also independent of bone formation [2].
Several tissues constitute the skeletons, including bone, bone
marrow, periosteum, perichondrium and cartilage. Therefore, it is
possible that cells other than osteoblasts or osteoclasts are involved
in bone remodeling. Mesenchymal stem cells (MSCs), first isolated
and referred as mechanocytes or CFU-F cells by Friedenstein [3],
can be derived from the bone marrow [4], trabecular bone [5] or
dental root [6], have the capacity of self-renewal and can
differentiate into several distinct cell types, including osteoblasts
and adipocytes. The differentiation of MSCs into either osteoblasts
or adipocytes is exclusively and transcriptionally regulated by two
key transcription factors, Runx2 (also called Cbfa1) and PPARc,
respectively [7–11]. An inverse relationship between the differen-
tiation of adipocytes and osteoblasts was demonstrated in cell and
animal models and was found in various human diseases [12]. For
example, decreased bone formation is accompanied by an increase
in bone marrow adipogenesis in age-, immobility- and corticoste-
roid-associated osteoporosis [13–15]. However the signaling
pathways and molecular mechanisms that regulate this still remain
largely unknown [16].
Cyclic 39,59-adenosine monophosphate (cAMP) is a key
intracellular signaling molecule, whose main function is to activate
the cAMP-dependent protein kinase A (PKA). PKA is a
heterotetrameric holoenzyme containing a regulatory (R) subunit
dimer and two catalytic (C) subunits. PKA is activated when four
molecules of cAMP bind to the R subunit dimer, two to each R
subunit, releasing two free active C subunits responsible for
phosphorylation of key substrates [17]. The cAMP/PKA signaling
pathway critical in phenotypic specification and transition in the
adult and developing central nervous systems (CNS) has also been
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primary or cloned neural precursor cells derived from the CNS
[18,19], and induce neuronal differentiation and neurite out-
growth in MSCs [20]. An elevated plasma and urinary cAMP has
long been found in osteoporotic patients [21], however, it is
unclear where cAMP/PKA signaling plays an important role in
controlling bone homeostasis and regulating cyto-differentiation of
MSCs. In an attempt to investigate this issue in the current study,
we indeed found that the addition of stimulators of cAMP/PKA
signaling in a defined adipocyte induction medium (AIM)
enhanced MSC adipogenesis and also found that cAMP/PKA
signaling inhibited MSC osteogenesis. Thus, the current study
provides a possible molecular mechanism for the reciprocal
relationship between adipogenesis and osteogenesis, a well known
differentiation phenotype.
Methods
Cells
Primary MSCs were isolated from iliac crest of donors with
informed consents and grown in DMEM-LG (Invitrogen, Grand
Island, NY) supplemented with 10% fetal bovine serum (FBS,
Invitrogen), 100 U/ml penicillin, 10 Ag/ml streptomycin, and
0.25 mg/ml amphotericin B at 37uC under 5% CO2 atmosphere.
The medium was changed twice a week and a subculture was
performed at 1:3 to 1:5 split every week. The human MSC strain
has been described previously and was originally derived from the
bone marrow of a 61-year-old female donor. This strain has been
transfected with a plasmid containing the type 16 human
papilloma virus proteins E6/E7 [22]. This strain is now referred
to as KP-MSCs and grown in the same culture condition with
primary MSCs. Using flow cytometry, KP-MSCs express CD29
(a1 integrin), CD44 (hyaluronan receptor), CD90 (Thy-1), CD105
(endoglin), SH2, and SH3 (MSC markers). KP-MSC cells were
harvested and used at passages 28–32.
Cytodifferentiation and cell treatments
One day before the initiation of differentiation, cells were
seeded in growth medium at a density of 10,000 cells/cm
2. For
adipogenic induction, the cells were washed twice with PBS
(Phosphate buffered saline) and treated in a defined Adipogenic
Induction Medium [AIM: DMEM-LG supplemented with 10%
FBS, 50 mg/ml ascorbate-2 phosphate (Sigma, St. Louis, MO),
10
27 M dexamethasone (Sigma), 50 mg/ml indomethacin (Sigma),
and 10 mg/ml insulin (Sigma)]. For experiments investigating
cAMP/PKA modulators on adipogenic differentiation, cells were
treated in AIM with the addition of 0.45 mM 3-isobutyl-1-
methylxanthine (IBMX), (Calbiochem, La Jolla, CA), 100 mM
forskolin (Calbiochem), 11 mM Sp-cAMP (Calbiochem), 20 mM
PKI (Sigma), or 11 mM Sp-cAMP+20 mM PKI. Medium was
changed every 3 days. After the appearance of morphologic
features of differentiation, cells were used for histochemical study.
Histochemical study
Cells were washed twice with PBS, fixed in 10% formalin for
over 1 hour at room temperature, and stained with Oil Red-O
(Sigma) to show adipogenic differentiation for 2 hours. The Oil
Red-O working solution was prepared by mixing 15 ml of a stock
(0.5% in isopropanol) and 10 ml of distilled water and filtering
through a PDVF membrane (0.2 mm) filter. Quantification of lipid
accumulation was achieved by extracting Oil Red-O from stained
cells with isopropanol and measuring the OD of the extract at
510 nm using an ELISA reader (Sepctra MAX 250; Molecular
Devices, Sunnyvale, CA).
Measurement of leptin secretion
Leptin secretion was measured using commercially available
ELISA kits according to the manufacturer’s instructions (Bio-
Source International, Camarillo, CA) to determine the concen-
tration of leptin in the conditioned medium of cells cultured in
complete growth medium or in AIM with or without the PKA
modulators.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted using the Trizol reagent (Invitrogen)
according to the manufacturer’s specifications. First strand cDNA
synthesis was performed using Superscript III reverse transcriptase
(Invitrogen), Random primer (Invitrogen), 10 mM dNTPs (In-
vitrogen), 56 First Strand synthesis buffer, 0.1 M DTT, and
RNaseOUT ribonuclease RNase inhibitor (Invitrogen). PCR was
performed using cDNA as the template in a 50 ml reaction mixture
containing a specific primer pair of each cDNA according to the
published sequences (Table 1). Each cycle consisted of the
following three steps: denaturation for 45 sec at 94uC, annealing
for 1 min at 51–58uC, and 90 sec of elongation at 72uC. The
reaction products were resolved by electrophoresis on a 1.5%
agarose gel and visualized with ethidium bromide.
Real-Time RT PCR
Expressions of the target gene PPARc2, Runx2, RANKL, OPG
and the endogenous reference GAPDH were quantified using
primers, probes, and standards. The primers and TaqMan probes
were designed using the software Primer Express (Applied
Biosystems, Warrington, UK). RT-PCR was performed according
to a TaqMan two-step method using an ABI PRISM 7700 sequence
detection system (Applied Biosystems). The non-template controls,
standard dilutions, and tumor samples were assayed. Total RNA
isolated from MSCs treated in various conditions was reversely
transcribed to cDNAusing anoligo deoxythymidine primer. A 20 ml
volume of PCR reaction mixture was used containing 50 ng of the
sample cDNA: 9 ml; 206 Target Assay Mix or 206 Endogenous
Table 1. PCR primers
Gene Sequence (Sense and antisense)
Product size
(bP)
b-actin 59-GCACTCTTCCAGCCTTCCTTCC-39 515
59-TCACCTTCACCGTTCCAGTTTTT-39
PPARc25 9-CCTATTGACCCAGAAAGCGATTC-39 595
59-GCATTATGAGACATCCCCACTGC-39
LPL 59-TGTAGATTCGCCCAGTTTCAGC-39 490
59-AAGTCAGAGCCAAAAGAAGCAGC-39
Runx2 59-GTTTGTTCTCTGACCGCCTC-39 318
59-CCAGTTCTGAAGCACCTGA-39
Osteopontin 59-CTAGGCATCACCTGTGCCATACC-39 373/331
59-CAGTGACCAGTTCATCAGATTCATC-39
Leptin 59-TCTTGTGGCTTTGGCCCTATCT-39 181
59-CCAGTGTCTGGTCCATCTTGGATA-39
RANKL 59-AATAGAATATCAGAAGATGGCACTC-39 486
59-TAAGGAGGGGTTGGAGACCTCG-39
OPG 59-GCTAACCTCACCTTCGAG-39 324
59-TGATTGGACCTGGTTACC-39
doi:10.1371/journal.pone.0001540.t001
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or without AmpErase UNG): 10 ml (Applied Biosystems). The PCR
cycling conditions included an initial phase of 2 min at 50uC,
followed by 10 min at 95uC for AmpErase, 45 cycles of 15 min at
95uCa n d1m i na t6 0 uC. Real-time amplification of the genes for
PPAR c2 (product number Hs00234592_m1), Runx2 (product
number Hs00231692_m1), RANKL (product number
Hs00243519_m1), OPG (product number Hs00171068_m1), and
GAPDH (product number Hs99999905_m1) was performed using
the ABI Assays on Demand primers and TaqmanH universal PCR
master mix on the ABI 7500 real-time PCR machine according to
the manufacturer’s instructions (Applied Biosystems). Analysis of the
results was carried out using the software supplied with the machine.
The software calculates PPAR c2, Runx2, RANKL and OPG
expression relative to the GAPDH housekeeper gene (delta CT) and
then relative to controls (delta delta CT) using the fluorescence
threshold of the amplification reaction and the comparative CT
method.
Western blot analysis
Protein was extracted from subconfluent cell cultures. The cells
(8610
5) were rinsed with PBS and lysed in 0.2 ml of protein
extraction reagent (M-PER, Pierce, Rockford, Illinois) plus protease
inhibitor cocktail (Halt
TM, Pierce) for 5 min on ice. Protein
concentrations were determined using the BCA assay (Pierce). After
being heated for 5 min at 95uC in a sample buffer, equal aliquots of
the cell lysates were run on a 10% SDS polyacrylamide gel. Proteins
were transferred to PVDF membrane filters. The filter was blocked
for 1 hour with TBS containing 5% nonfat dry milk and 0.05%
Tween 20 and then incubated overnight at 4uC with the primary
antibodies. The filter was washed 3 times for 10 minutes each with
TBS containing 0.05% Tween 20. Bound primary antibodies were
detected by incubating for 1 hour with horseradish peroxidase-
conjugated goat anti-mouse or anti-rabbit IgG (BD PharMingen,
San Diego, CA). The filter was washed and developed using a
chemiluminescence assay (Perkin Elmer Life Science, Inc., Boston,
MA). Densitometric analysis was carried out using Image Master 2D
Elite software (Amersham Biosciences). Activation of CREB was
detected by Western blot analysis of the phosphorylation state using
phospho-CREB antibodies (Cell Signaling Technology). The level of
CREB phosphorylation was calculated as the density ratio of bands
corresponding to pCREB and CREB.
Protein kinase A catalytic activity assays
cAMP-dependent PKA activities were assayed using the
PepTag Assay for nonradioactive detection of PKA (Promega,
Madison, WI) on the basis of the phosphorylation of fluorescent-
tagged PKA-specific peptides. The cell lysate for PKA protein was
prepared using a hypotonic extraction buffer (20 mM Tris, pH
7.5, 5 mM EDTA, 1 mM PMSF, and 10 mg/ml aprotinin).
Aliquots of the PKA preparation and PKA catalytic subunit as a
positive control were incubated for 30 min at 30uC in PepTag
PKA 56 reaction buffer (100 mM Tris-HCl, pH 7.4, 50 mM
MgCl2, and 5 mM ATP) and 0.4 mg/ml of the PKA-specific
peptide substrate PepTag A1 (L–R–R–A–S–L–G; Kemptide). The
reaction was stopped by heating for 10 min at 95uC. Phosphor-
ylation of the PKA-specific substrates was used to measure kinase
activity. Phosphorylated and unphosphorylated PepTag peptides
were separated on a 0.8% PH 8.0 Tris-HCl agarose gel by
electrophoresis. For the PKA assays, 10 mg of protein was applied.
DNA delivery methods
For transfection of cells with pmaxGFP or pcDNA3 or
pcDNA3-CREBR287L, Nucleofector technology (AMAXA Bio-
systems, Cologne, Germany) was used with each nucleofection
sample containing 4 mg of DNA, 4610
5 cells, and 100 mlo f
Human MSC Nucleofector Solution. The transfection was carried
out under the program C-17 of the Nucleofector device, as
recommended by the manufacturer. The transfected cells were
then suspended in an appropriate volume of 20% FBS
supplemented DMEM-LG medium and seeded for further culture.
After 24 hours of incubation, the medium was replaced by AIM
with 100 mM Forskolin for 3 days. The efficiency of transfection as
evaluated by the expression of EGFP in cells transfected with
pmaxGFP vector was more than 50%.
Zebrafish maintenance and histological staining
Zebrafish embryos were maintained in Embryo Medium at
28uC. To visualize developing bone, the embryos were immobi-
lized in ice water, then fixed for 24 hours in buffered 4%
paraformaldehyde. After washing twice in PBS, they were
dehydrated in 50% and 100% ethanol each for 24 hours. They
were placed in 0.05 mg/ml Alcian Blue in 3:7 glacial acetic acid :
100% ethanol for 20 min. Alcian Blue-stained zebrafish were then
cleared in 1% KOH for one hour. The fish were then transferred
to 2 mg/ml Alizarin Red in 1% KOH for 1 hour and cleared in
20% glycerol in 1% KOH for 40 min. Alizarin Red-stained
zebrafish were photo-pictured or preserved in 50% and then 80%
glycerol in 95% ethanol, followed by 100% glycerol.
Raman microspectroscopic study
Each specimen for spectroscopic study was dried at 25uC, 50%
relative humidity (RH) for one week, and then immediately
measured. The biophysical characteristics and molecular compo-
sitions of the excised samples were determined by using a
dispersive micro-Raman spectrophotometer (Ventuno, Jasco Co.,
Tokyo, Japan) equipped with a 30 mW green (532 nm) solid-state
laser as standard. The pixel resolution was 1.3 cm
21. The spectra
were obtained in the 400–4000 cm
21 range [23].
Vibrational spectroscopic study
The calcified sample was dried for one week at 25uC, 50% RH
condition, and then used for spectral investigation to determine its
biophysical characteristics and molecular compositions by using
both Fourier transform infrared (FTIR) microspectroscopy (Micro
FTIR-200, Jasco Co.) with transmission technique and confocal
micro-Raman spectrophotometer (Ventuno, Jasco Co., Tokyo,
Japan) equipped with a 30 mW green (532 nm) solid-state laser as
standard via non-destructive analysis [23].
Results
PKA stimulators enhance adipogenesis, inhibit
osteogenesis and decrease the ratio of RANKL/OPG gene
expression
In a first attempt to identify the optimal conditions for
adipogenic differentiation, we found that the addition of 3-
isobutyl-1 methyl xanthine (IBMX) significantly increased adipo-
genic differentiation by primary MSCs (Figure S1). Because IBMX
is a phosphodiesterase inhibitor which prevents cAMP degrada-
tion to activate PKA, the cAMP/PKA pathway is hypothesized to
stimulate adipogenesis. The primary MSCs have limited life span
with an average number of population doublings of 38 and tend to
change their differentiation potential during in vitro expansion
[24]. Furthermore, the usual methods that are used for
transfection are not easily applied in primary MSCs. Therefore,
a previously developed KP-MSC line and primary MSCs were
used in the current study to extend the stimulatory effect of IBMX
cAMP/PKA and Differentiation
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signaling pathway in MSC differentiation, we first compared the
effects of several modulators of the cAMP/PKA pathway,
including stimulators such as IBMX, forskolin, and Sp-cAMP,
inhibitors such as PKI and combinations of both on the
adipogenesis of MSCs by measuring Oil Red-O staining (Fig. 1A
and 2A). Both KP- and primary MSCs treated in AIM began to
initiate adipogenesis, and the extension of treatment for 2 weeks
significantly increased the intensity of Oil Red-O staining (Fig. 1A
and 2A). However, incubation of KP-MSCs in a complete growth
medium did not induce any increase in Oil Red-O staining,
suggesting that the cells did not undergo spontaneous differenti-
ation into adipocytes. Interestingly, IBMX added in AIM further
increased Oil Red-O staining both at 7 and 14 days (Fig. 1B and
2B). The substitution of IBMX with either forskolin or Sp-cAMP
significantly increased Oil Red-O staining at day 14 in comparison
with the AIM group. The addition of PKI in AIM did not cause
any significant change in Oil Red-O staining, whereas, PKI
significantly inhibited the stimulatory effect of IBMX , forskolin or
Sp-cAMP on Oil Red-O staining as compared with the IBMX ,
forskolin or Sp-cAMP group at 14 days (Fig. 1B and 2B).
Meanwhile, the effect of IBMX, forskolin or Sp-cAMP on lipid
vesicle appearance was also inhibited by the addition of PKI (data
not shown).
The effects of PKA modulators on KP-MSC adipogenesis was
further investigated by RT-PCR to determine the mRNA
expression of the key transcription factor, PPARc2, and a lineage
marker of adipocytes, LPL (Fig. 1C). PPARc2 and LPL were not
detected from cells in complete growth medium at 7 and 14 days
or in AIM at day 7, but they could be detected in AIM at day 14,
further confirming the initiation of adipogenesis in AIM but not in
the complete growth medium. When adding IBMX or other PKA
stimulators such as forskolin and Sp-cAMP in AIM, the expression
of PPARc2 and LPL mRNA was up-regulated either at 7 or
Figure 1. PKA modulators influence adipogenesis, gene expression for adipogenesis, osteogenesis and osteoclast-inducing factors
in KP-MSCs. (A) Enhancement of adipogenesis by IBMX, forskolin and Sp-cAMP. Cells were treated in complete growth medium [C] or in adipocyte
induction medium without [A] or with the indicated modulator of PKA activity [I: IBMX (0.45 mM), F: forskolin (100 mM), S: Sp-cAMP (11 mM), P: PKI
(20 mM), S+P: Sp-cAMP+PKI] for 7 and 14 days. Differentiated adipocytes were detected by the accumulation of lipids, which were stained with Oil
Red O. (B) Oil Red O staining as OD510. The results displayed in the bar graphs are quantitative analytic data from three independent experiments
and are presented as the meanSD values. Each ratio was normalized to the control, and significance was determined by Student’s t-test. (* p,0.05
versus C;
# p,0.05,
## ,0.01 versus A,
###p,0.05 versus S). RT-PCR analysis of gene expression of makers for adipogenesis (C), osteogenesis (D),
and osteoclast-inducing factors (E) after treatment with PKA modulators.
doi:10.1371/journal.pone.0001540.g001
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change in mRNA expression of PPARc2 and LPL, whereas, PKI
decreased the stimulator effect of Sp-cAMP on mRNA expression
of these two genes. Levels of mRNA expression analyzed by real-
time RT-PCR in primary MSCs also revealed the same results.
Treatment with IBMX and forskolin significantly induced the
expression of PPARc2 and the addition of PKI at the same time
blocked the inductive effects (Fig. 2C). These results all together
suggest a stimulatory role of cAMP/PKA signaling in MSC
adipocyte differentiation and a low stimulation of cAMP/PKA
signaling in cells treated with AIM.
An inverse relationship between MSC adipogenesis and
osteogenesis was well known, therefore, we further investigated
the effect of cAMP/PKA signaling pathway on gene expression of
Runx2, the earliest transcription factor of osteoblast differentiation
[7,8], and one osteoblast lineage markers, osteopontin (OP)
(Fig. 1C). The level of Runx2 expression was low in cells treated
in complete growth medium, and increased after the extension of
the culture period for 14 days. This data support the previous
finding that MSCs underwent spontaneous differentiation into
osteoblasts when the cells reached confluence. The level of Runx2
expression did not significantly increase in cells treated in AIM
with or without any PKA stimulators. However, a substantial
increase in Runx2 expression was observed in cells treated with
PKI, suggesting the stimulatory effect of PKA inhibitor on MSC
osteogenesis (Fig. 1D). Furthermore, cells treated in AIM without
or with the PKA modulators for 14 days, which all expressed
PPARc2, did not express any gene expression of Runx2, indicating
the inverse relationship between adipogenesis and osteogenesis by
MSCs. Cells in growth medium expressed OP and alkaline
phosphatase (data not shown) gene expression, suggesting these
genes are not exclusively expressed by osteoblasts. However, the
gene expression of OP was down-regulated in cells treated in AIM
with the addition of a PKA stimulator, including IBMX, forskolin
and Sp-cAMP at 7 or 14 days as compared with the expression in
AIM (Fig. 1D). Expression of Runx2 mRNA was also significantly
increased in primary MSCs when treated with PKI (Fig. 2D).
These results all together suggest an inhibitory role of cAMP/PKA
signaling in MSC osteoblast differentiation.
Receptor Activators of NF-kB Ligand (RANKL) and osteopro-
tegerin (OPG, a decoy receptor for RANKL) coordinate with one
another to play a critical role in the regulation of osteoclast
formation, and the relative presence of RANKL and OPG dictates
osteoclastogenesis [25,26]. PKA stimulators such as IBMX, forskolin
and Sp-cAMP, which stimulated the expression of PPARc2,
inhibited the expression of RANKL (day 7 versus 14), stimulated
the expression of OPG (day 7 versus 14), and thus decreased the
RANKL/OPGratio(Fig.1E).Ontheotherhand,inhibitorsofPKA
activity, which stimulated the expression of Runx2, inhibited the
expressionofOPG(Sp-cAMP+PKI versusPKIinday7 andday14),
and thereby increased the RANKL/OPG ratio (Fig. 1E). Consistent
with the effect in KP-MSCs, PKI also significantly increased the
ratio of RANKL/OPG gene expression of primary MSCs when
treated in AIM with or without PKA stimulators (Fig. 2E). These
data suggest that osteoblast differentiation in MSCs, which is
inhibited by cAMP/PKA signaling, is associated with an increase in
the RANKL/OPG gene expression ratio.
PKA stimulators stimulate adipogenesis, inhibit
osteogenesis and increase osteoclast-inducing potential
via suppressing leptin expression and secretion
Leptin is highly expressed and secreted by adipocytes residing in
bone marrow and fat tissues [27]. The leptin secretion from
adipocytes, however, is stimulated by insulin, one component of
AIM [28,29], and is also regulated by subtracts modulating PKA
activity [30]. We, therefore, investigated the role of leptin in PKA
stimulators-mediated stimulation of adipogenesis-dependent gene
expression, inhibition of osteogenesis-dependent gene expression,
and decrease in the ratio of RANKL/OPG gene expression in
MSCs. First, we measured leptin levels in cells treated in AIM with
or without PKA modulators. The baseline for leptin concentration
in a conditioned medium (CM) from cells treated in AIM was
around 600 pg/10
4 cells both at 1 and 2 weeks. Treatment with
PKA stimulators such as IBMX, forskolin and Sp-cAMP
significantly inhibited leptin secretion, although there is less
inhibition with Sp-cAMP (Fig. 3A). However, PKA inhibitors
caused a significant increase in leptin secretion only at 2 weeks,
when comparing the treatments with Sp-cAMP and with Sp-
cAMP+PKI (Fig. 3A). We, then, studied the expression of mRNA
encoding for leptin as a possible explanation for the decrease in
leptin secretion. At first, we found that MSCs expressed mRNA
for leptin receptor (OB-R), and neither incubation in AIM nor
treatment with PKA stimulators or inhibitors caused any
significant change. The baseline for leptin mRNA (OB) in AIM
was detectable, and the treatment with PKA stimulators greatly
decreased leptin gene expression (Fig. 3B). Coincident with the
Figure 2. PKA modulators influence adipogenesis, gene expres-
sion for adipogenesis, osteogenesis and osteoclast-inducing
factors in primary MSCs. (A) Enhancement of adipogenesis by IBMX
and forskolin. Cells were treated in complete growth medium [C] or in
adipocyte induction medium without [A] or with the indicated modulator
ofPKAactivity[I:IBMX(0.45 mM),F:forskolin(100 mM),P:PKI(20 mM),I+P:
IBMX+PKI, F+P: forskolin+PKI] for 7 and 14 days. Differentiated adipocytes
were detected by the accumulation of lipids, which were stained with Oil
Red O. (B) Oil Red O staining as OD510. The results displayed in the bar
graphs are quantitative analytic data from three independent experi-
ments and are presented as the meanSD values. Each ratio was
normalized to the control, and significance was determined by Student’s
t-test. (** p,0.01 versus C;
# p,0.05,
## ,0.01 versus A,
###p,0.05
versus I or F). Real-Time RT-PCR analysis of the gene expression ratio of
PPARc2/GADPH (C), Runx2/GADPH (D), and RANKL/OPG (E) after
treatment with PKA modulators for 7 days.
doi:10.1371/journal.pone.0001540.g002
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expression to a lesser degree. Interestingly, there was a great
increase in leptin gene expression at 2 weeks of cells treated in
AIM with IBMX, even though the leptin secretion in these cells
was still far below baseline. However, the removal of IBMX from
the medium in these cells induced leptin secretion (data not
shown). These results are compatible with previous reports that
leptin was secreted by adipocytes and suggest IBMX has a direct
effect in inhibiting leptin expression and secretion.
To address whether PKA stimulators-mediated leptin suppres-
sion may be required for their regulation of MSC differentiation,
namely induction of adipogenesis and inhibition of osteogenesis,
we investigate whether the effects of PKA stimulators would be
blocked by adding leptin exogenously. This was then demonstrat-
ed by the addition of exogenous leptin in cells treated in AIM with
forskolin, which inhibited PPARc2 expression, stimulated Runx2
expression and increased the ratio of RANKL/OPG in a dose-
dependent manner (Fig. 3C). The effects of exogenous leptin on
regulating adipogenic, osteogenic and osteoclast-inducing factor
gene expressions were also demonstrated in cells treated in AIM
with IBMX when evaluated by real time PCR (Fig. 3D–F). These
data clearly answer that PKA stimulators induce adipogenesis,
inhibit osteogenesis and decrease the RANKL/OPG gene
expression ratio via suppressing leptin expression and secretion.
PKA stimulators increase phosphorylation of CREB to
regulate expression of leptin, PPARc and Runx2 and the
ratio of RANKL/OPG
To determine whether PKA stimulators activate PKA in MSCs,
cells were treated inAIM with IBMX, and PKA activity was assayed
in serum-free conditions. Cells treated by serum depletion for
48 hours expressed a baseline of PKA activity, and the level of PKA
activation increased immediately, reaching its peak, about threefold
of baseline, at 2 hours after induction and gradually returned to the
baseline at 24 hours after induction (Fig.4A). In a separate
experiment with PKA activity analyzed at 2 hours after induction,
while cells in IBMX or forskolin-containing AIM still expressed
about twofold PKA activity, addition of the PKA inhibitor, PKI,
blocked the activation of PKA by IBMX or forskolin (Fig. 4B). The
CREB-binding protein transcriptional coactivator is an important
regulator of gene expression through its ability to interact and
cooperate with several transcription factors, such as CREB in
response to cAMP/PKA signaling. Like its effect on modulating
PKA activities in an induction medium, IBMX in AIM also
phosphorylated CREB. CREB phosphorylation reached a peak
level,morethanfourfoldthe baseline,at2 hoursafterinduction,and
maintained a twofold expression of the baseline level after 24 hours
ofinduction(Fig.4Cand4D).SimilartotheblockofPKAactivityby
PKI, phosphorylation of CREB by IBMX or forskolin was also
blocked by the addition of PKI (Fig. 4E).
To directly assess the participation of CREB in directing
differentiation into adipocytes or osteoblasts and controlling the
ratio of RANKL/OPG, a control or a dominant-negative (DN)
CREB plasmid, pcDNA3-CREBR287L, was transfected into
MSCs before the initiation of differentiation (Fig. 4F). When
compared with the control vector, transfection with DN CREB
stimulated leptin expression, decreased PPARc2 expression,
increased Runx2 expression, and increased the ratio of
RANKL/OPG gene expression (Fig. 4G). These results demon-
strate that cAMP/PKA/CREB pathway regulates cyto-differenti-
ation and osteoclast-inducing potential of MSCs.
Leptin blocks PKA stimulator-induced bone loss in
developing zebrafish
To investigate the in vivo role of activation of cAMP/PKA
signaling on bone development, we used a zebrafish vertebrate
model system. Since bone development is progressively increased
at the beginning of larval stage embryos, IBMX treatment was
initiated at 2 dpf (days after fertilization) [31]. The IBMX-treated
embryos survived and had normal morphology for up to 8 dpf
(Fig. 5A). Bone development was visualized in whole embryos by
Alizarin Red S staining (Fig. 5B), along with hematoxylin-and-
eosin staining of thin sections (Fig. 5C). In normal and vehicle
(DMSO)-treated control embryos, mineralization as indicated by
positive Alizarin Red S staining was apparent at the otoliths, and
extensive skeletal development was evident in the cranial and
Figure 3. PKA stimulators regulate gene expression for
adipogenesis, osteogenesis and osteoclast-inducing factors
by suppressing leptin. (A,B) Suppression of leptin secretion and
transcription by IBMX, forskolin and Sp-cAMP. Cell treatments were the
same as Fig. 1. (A) Leptin concentrations in the conditioned medium of
the last 2 days were measured by ELISA and normalized by cell
numbers. The figure shows representative data from two independent
experiments with three replicates for each condition; data are
presented as the meanSD values, and significance was determined by
Student’s t-test. (**,0.01 versus A;
#,0.05 versus S) (B) RT-PCR analysis
of mRNA for leptin and b-actin. (C) Exogenous leptin inhibits forskolin-
induced effects on gene expression of PPARc2 and Runx2 and the
RANKL/OPG gene expression ratio. Cells were cultured in complete
growth medium [C] or treated in AIM with 100 mM forskolin [F] in the
absence or presence of leptin (0.6, 1.5, 3 mg/ml) for 7 days. RT-PCR
analysis for b-actin, PPARc2, Runx2, RANKL and OPG. Real-Time RT-PCR
analysis of the gene expression ratio of PPARc2/GADPH (D), Runx2/
GADPH (E), and RANKL/OPG. (F). Exogenous leptin inhibits the effects
of AIM with IBMX (I: AIM with 0.45 mM IBMX) on gene expression of
PPARc2, Runx2 and the RANKL/OPG gene expression ratio.
doi:10.1371/journal.pone.0001540.g003
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bone formation was observed in any of the IBMX-treated embryos
at 8 dpf (n=19). Although, leptin was identified in fish using an
antibody against mouse leptin, the fish leptin is still not isolated
[32]. Therefore, we use leptin both from human and mouse to
investigate leptin effects on zebrafish bone formation. Interesting-
ly, human and mouse leptin block IBMX-induced bone loss both
at 0.6 and 1.5 mg/mL (H-L1, n=14; H-L2, n=15; M-L1, n=17;
M-L2, n=14). These results were further evidenced by micro-
scopic Raman spectroscopy (Fig. 5D). All of the embryos displayed
a similar peak at 1007 cm
21 that is assigned to phenylalanine and
frequently maintains unchanged at different samples. A unique
feature in the Raman spectrum of IBMX-treated embryos was a
lack of the large peak at 961 cm
21 and 1095 cm
21 corresponding
to the n1 symmetric stretching mode of the phosphate group of
hydroxyapatite and the C-C stretching mode of protein/
phosphate stretching mode of DNA and RNA, respectively
(Fig. 5D). The former is an indication of bone formation, the
latter is a predominant signal of DNA/RNA formation [33]. The
value of peak intensity ratio of 961 cm
21/1007 cm
21,a sa
Figure 4. PKA stimulators increase phosphorylation of CREB to regulate gene expression of leptin, PPARc2 and Runx2 and the
RANKL/OPG ratio. Cells were treated in AIM with IBMX (0.45 mM) after serum starvation for 48 hours. (A) PKA activity increased immediately and
reached the peak at 2 hours and gradually returned to the baseline at 24 hours. (B) Cells were treated in AIM with different combinations of IBMX
(0.45 mM), forskolin (100 mM), and PKI (20 mM), and PKA activities were measured at 2 hours after treatment. (C,D) The same experiment of (A).
Level of CREB phosphorylation was indicated as ratio of pCREB/CREB protein level. (E) The same experiment of (B) Levels of CREB phosphorylation
were measured at 2 hours after treatment. Data are presented as the mean6SD values of three separate experiments, and significance was
determined by Student’s t-test. (* p,0.05, ** p,0.01 versus the baseline). (F,G) Suppression of forskolin-induced modulation of gene expression of
leptin, PPARc2, Runx2, RANKL and OPG by transfection with DN CREB. Cells were transfected with control (pcDNA3) or DN CREB vector for 48 hours,
followed by treatment in AIM with forskolin (100 mM) for 3 days. (F) Western blot analysis of CREB protein in the transfected cells. (G) RT-PCR analysis
of gene expression in transfected cells. Transfection with DN CREB abrogated forskolin-induced block of leptin expression, initiation of PPARc2
expression, and inhibition of Runx2 expression, and increased the ratio of RANKL/OPG gene expression.
doi:10.1371/journal.pone.0001540.g004
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and 0.91 for DMSO, IBMX and IBMX with leptin, respectively.
The similar value of 1095 cm
21/1007 cm
21 for DMSO and IBMX
with leptinsuggests that both samples hadthesamephosphate group
in the backbone conformations of RNA and DNA after embryo
development, as compared with the smaller value of 1095 cm
21/
1007 cm
21 for IBMX. These findings confirm a critical role for
leptin involvement in cAMP/PKA signaling-mediated in vivo bone
lossindevelopingzebrafish.Wewereunabletoinvestigatetheroleof
leptin in adipogenesis in these embryos, because adipocytes have not
been described in teleosts, and in other vertebrate species, fat
deposition does not occur until the postnatal period.
Discussion
The cAMP/PKA pathway has been demonstrated in 3T3-L1
cells, murine preadipocytes, to stimulate adipogenesis by activating
the transcriptionfactor CREB [34,35]. However the directeffects of
cAMP/PKA on the differentiation of MSCs are not well studied. In
the current report, we explored the direct involvement of cAMP/
PKA signaling in regulating MSC differentiation and its ability to
control osteoclastogenesis. The addition of PKA stimulators in AIM
enhanced Oil Red-O staining and the expression of markers for
adipocytes (PPARc2 and LPL), inhibited the expression of markers
for osteoblasts (Runx2 and Op), and increased the RANKL/OPG
ratio at the mRNA level. We further demonstrated that PKA
stimulators repressed leptin synthesis and secretion in MSCs and
that the effects of PKA stimulators on MSCs were blocked by the
administration of exogenous leptin. These data suggest that PKA
stimulators exerted their effects on MSCs via the repression of
endogenous leptin. Furthermore, the direct participation of CREB
in the effects of PKA stimulators was demonstrated through the use
of a DN CREB plasmid, which blocked the effects of the PKA
stimulator when transfected into cells before differentiation. These
results suggest that cAMP-dependent PKA activity is sufficient to
increase CREB activity and to regulate three distinct lineage
differentiations (adipogenesis, osteogenesis and osteoclastogenesis)
that are involved in bone homeostasis.
Figure 5. Leptin abrogates IBMX-induced lack of skeletal ossification in developing zebrafish. Embryos were treated in vehicle DMSO,
IBMX (0.045 mM), and IBMX with human [H] or mouse [M] leptin (L1: 0.6 mg/mL, L2: 1.5 mg/mL) at 2 dpf. (A) Morphology of embryos at 8 dpf. (B)
Alizarin Red S and alcian blue staining of whole zebrafish reveals normal skeletal ossification in DMSO-treated embryos at otolith (arrow), while
absent skeletal ossification is evident in IBMX-treated embryos. The addition of human and mouse leptin both in low and high concentrations
abrogates IBMX-induced absence of skeletal ossification. (C) Hematoxylin-and-eosin staining of zebrafish sections reveals impaired bone
development in IBMX-treated embryos. Arrows indicate bone development with cell aggregation at otolith and pharyngeal arches. (D) Raman
microspectroscopic analysis of bone development at otolith in zebrafish.
doi:10.1371/journal.pone.0001540.g005
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of gene expression were inconsistent in some situations, such as the
mRNA level of Runx2 after stimulation with Sp-cAMP for 7 days.
To understand the underlying mechanism, the abilities of these
three reagents to activate PKA have been compared with those of
IBMX and forskolin stronger than that of Sp-cAMP (data not
shown), which may be used to explain how cells treated with Sp-
cAMP still expressed Runx2.
In vitro studies established that leptin enhanced the osteogenesis
of human stromal cells, increased mineralization of the extracel-
lular matrix, but inhibited adipogenesis [36,37]. Similar findings
have been obtained with other cell models [38]. However, it is not
clear from the animal studies whether leptin is a stimulator or an
inhibitor of bone growth, as intracerebroventricular infusion of
leptin affects bone mass and returns the high bone mass phenotype
in ob/ob mice back to wild-type levels [39], whereas systemic
administration has been reported to induce loss of bone marrow
adipocytes and increase bone formation in ob/ob mice [27,40,41]
and to reduce bone loss in ovariectomized rats [42] and in tail-
suspended female rats [43]. In the current study, we found that the
induction of adipogenesis in MSCs was associated with a decrease
in leptin secretion and gene expression. The suppression of leptin
expression is believed to play a role in the initiation of adipogenesis
because the administration of exogenous leptin inhibited adipo-
genesis. The addition of exogenous leptin from 0.6 to 3 mg/mL
not only inhibited the expression of PPARc2, but also stimulated
the expression of Runx2 and the ratio of RANKL/OPG gene
expression in a dose-dependent manner, indicating that leptin
functions as a molecule rheostat that modulates bone homeostasis.
Similar in in vitro MSC cultures, the role of leptin on bone
homeostasis was also demonstrated in bone development of the in
vivo zebrafish model. Although plasma leptin levels were reported
with diurnal variation and variant among individuals [44], a
significant relationship was observed between plasma leptin
concentration, and the bone mineral mass and density in healthy
elderly men and women [45], and the presence of vertebral
fractures in postmenopausal women [46]. These results further
support our finding that cAMP/PKA signaling inhibited bone
formation by suppressing leptin.
Bone formation has been studied over the past 20 years by
investigating the balance between osteoblast and osteoclast
function based on the concept that bone homeostasis is controlled
by these two cells. In the current paper, we propose a new bone
metabolic unit which highlights the role of MSCs, and upon which
we identified cAMP/PKA signaling, one of the many signaling
pathways that regulate bone homeostasis, which might determine
the constitution of the cellular components via directing
adipogenesis, osteogenesis and osteoclastogenesis by controlling
the release of leptin from MSCs (Fig. 6). This new concept has
been supported by a study on MSC differentiation, which has
shown that a 14-3-3-binding protein, TAZ, co-activates Runx2-
dependent gene transcription while repressing PPARc2-dependent
gene transcription [16]. The concept is further supported by a
most recent study by Zhao et al. [47]. They wisely identified 53
endogenous candidate suppressors of osteogenic specification by
screening a synthetic SiRNA library targeting 5,000 human genes,
which when silenced could initiate differentiation of MSCs into
osteoblasts. 11 of those selected SiRNAs inhibited adipogenic
differentiation of MSCs under conditions that induce adipogenic
differentiation. Furthermore, cAMP was also identified to play
opposing roles in osteogenesis vs. adipogenesis. The results from
this and other studies show that the MSCs may be used to
elucidate molecular signaling on the regulation of adult bone
homeostasis by investigating the potential to differentiate into
adipocytes and osteoblasts and to regulate osteoclastogenesis by
changing the ratio of RANKL/OPG gene expression.
Supporting Information
Figure S1 The adipogenic differentiation of primary MSCs as
demonstrated by Oil Red O staining. Primary MSCs were
induced in AIM with (A) or without (B) 0.45 mM IBMX for
3 weeks.
Found at: doi:10.1371/journal.pone.0001540.s001 (1.85 MB TIF)
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